SIRT2 inhibition protects against cardiac hypertrophy and ischemic injury
- Feinberg Cardiovascular and Renal Research Institute, Northwestern University School of Medicine, United States
Figures
Figure 1 with 1 supplement
SIRT2 is upregulated in heart failure (HF).
(A) SIRT1, SIRT2, SIRT3, and SIRT6 in mouse hearts after trans-aortic constriction (TAC). (B) SIRT2 in human hearts from healthy patients and patients with dilated cardiomyopathy. (C) SIRT2 protein …
-
Figure 1—source data 1
SIRT1, -2, -3, and -6 after sham and trans-aortic constriction (TAC) surgery as shown in Figure 1A.
- https://cdn.elifesciences.org/articles/85571/elife-85571-fig1-data1-v2.csv
-
Figure 1—source data 2
SIRT2 in non-failing and failing human hearts as shown in Figure 1B.
- https://cdn.elifesciences.org/articles/85571/elife-85571-fig1-data2-v2.csv
-
Figure 1—source data 3
SIRT2 in non-failing and ischemic human hearts as shown in Figure 1C.
- https://cdn.elifesciences.org/articles/85571/elife-85571-fig1-data3-v2.csv
-
Figure 1—source data 4
Full gels for Figure 1A–C.
- https://cdn.elifesciences.org/articles/85571/elife-85571-fig1-data4-v2.pptx
-
Figure 1—source data 5
Full gels for Figure 1A–C unedited.
- https://cdn.elifesciences.org/articles/85571/elife-85571-fig1-data5-v2.pptx
-
Figure 1—source data 6
Full gels for Figure 1A–C unedited.
- https://cdn.elifesciences.org/articles/85571/elife-85571-fig1-data6-v2.zip
Figure 1—figure supplement 1
SIRT2 protein in different mouse tissues, including the heart (A), and in various cell lines, including H9c2 cells (B).
-
Figure 1—figure supplement 1—source data 1
Full gels for Figure 1—figure supplement 1.
- https://cdn.elifesciences.org/articles/85571/elife-85571-fig1-figsupp1-data1-v2.pptx
-
Figure 1—figure supplement 1—source data 2
Full gels for Figure 1—figure supplement 1 unedited.
- https://cdn.elifesciences.org/articles/85571/elife-85571-fig1-figsupp1-data2-v2.pptx
Figure 2 with 1 supplement
Sirt2 deficiency protects the heart against cardiac dysfunction after trans-aortic constriction (TAC).
Sirt2-/- and wild-type (WT) littermates were subjected to TAC and ejection fraction (EF) (A), fractional shortening (FS) (B), and interventricular septal thickness during diastole (C) were assessed …
-
Figure 2—source data 1
Ejection fraction (EF) in wild-type (WT) and Sirt2-/- mice after sham or trans-aortic constriction (TAC) as shown in Figure 2A.
- https://cdn.elifesciences.org/articles/85571/elife-85571-fig2-data1-v2.csv
-
Figure 2—source data 2
Fractional shortening (FS) in wild-type (WT) and Sirt2-/- mice after sham or trans-aortic constriction (TAC) as shown in Figure 2B.
- https://cdn.elifesciences.org/articles/85571/elife-85571-fig2-data2-v2.csv
-
Figure 2—source data 3
Interventricular septal (IVS) thickness diastole in wild-type (WT) and Sirt2-/- mice after sham or trans-aortic constriction (TAC) as shown in Figure 2C.
- https://cdn.elifesciences.org/articles/85571/elife-85571-fig2-data3-v2.csv
-
Figure 2—source data 4
HW/BW in wild-type (WT) and Sirt2-/- mice after sham or trans-aortic constriction (TAC) as shown in Figure 2E.
- https://cdn.elifesciences.org/articles/85571/elife-85571-fig2-data4-v2.csv
-
Figure 2—source data 5
CSA in wild-type (WT) and Sirt2-/- hearts as shown in Figure 2G.
- https://cdn.elifesciences.org/articles/85571/elife-85571-fig2-data5-v2.csv
Figure 2—figure supplement 1
Expression of protein (A) and mRNA (B) of other sirtuin family members in the hearts of Sirt2-/- mice.
N=6. Data presented as mean ± SEM.
-
Figure 2—figure supplement 1—source data 1
mRNA levels of sirtuin proteins in wild-type (WT) and Sirt2-/- hearts as shown in Figure 2—figure supplement 1.
- https://cdn.elifesciences.org/articles/85571/elife-85571-fig2-figsupp1-data1-v2.csv
-
Figure 2—figure supplement 1—source data 2
Full gels for Figure 2—figure supplement 1.
- https://cdn.elifesciences.org/articles/85571/elife-85571-fig2-figsupp1-data2-v2.pptx
-
Figure 2—figure supplement 1—source data 3
Full gels for Figure 2—figure supplement 1 unedited.
- https://cdn.elifesciences.org/articles/85571/elife-85571-fig2-figsupp1-data3-v2.pptx
Figure 3
Hearts from Sirt2-/- mice are protected against ischemia-reperfusion (I/R) injury.
Ejection fraction (EF) and fractional shortening (FS) in wild-type (WT) and Sirt2-/- mice 7 (A) and 21 days (B) after I/R (N=4–5). (C) Time course of FS in Sirt2-/- mice after I/R injury (N=4–5). (D,…
-
Figure 3—source data 1
Ejection fraction (EF) and fractional shortening (FS) in wild-type (WT) and Sirt2-/- mice after ischemia-reperfusion (I/R) as shown in Figure 3A.
- https://cdn.elifesciences.org/articles/85571/elife-85571-fig3-data1-v2.csv
-
Figure 3—source data 2
Ejection fraction (EF) and fractional shortening (FS) in wild-type (WT) and Sirt2-/- mice after ischemia-reperfusion (I/R) as shown in Figure 3B.
- https://cdn.elifesciences.org/articles/85571/elife-85571-fig3-data2-v2.csv
-
Figure 3—source data 3
Time course of fractional shortening (FS) in wild-type (WT) and Sirt2-/- mice after ischemia-reperfusion (I/R) as shown in Figure 3C.
- https://cdn.elifesciences.org/articles/85571/elife-85571-fig3-data3-v2.csv
-
Figure 3—source data 4
Propidium iodide (PI) positive cells as shown in Figure 3E.
- https://cdn.elifesciences.org/articles/85571/elife-85571-fig3-data4-v2.csv
Figure 4 with 2 supplements
cs-Sirt2-/- hearts are protected against trans-aortic constriction (TAC) and ischemia-reperfusion (I/R).
Ejection fraction (EF) and fractional shortening (FS) in Sirt2f/f and cs-Sirt2-/- mice 7 (A) and 14 days (B) after TAC (N=5–9). (C,D) mRNA levels of Anf (C) and Bnp (D) in the hearts of Sirt2f/f and …
-
Figure 4—source data 1
Ejection fraction (EF) and fractional shortening (FS) in Sirt2f/f and cs-Sirt2-/- mice 7 days after ischemia-reperfusion (I/R) as shown in Figure 4A.
- https://cdn.elifesciences.org/articles/85571/elife-85571-fig4-data1-v2.csv
-
Figure 4—source data 2
Ejection fraction (EF) and fractional shortening (FS) in Sirt2f/f and cs-Sirt2-/- mice 14 days after ischemia-reperfusion (I/R) as shown in Figure 4B.
- https://cdn.elifesciences.org/articles/85571/elife-85571-fig4-data2-v2.csv
-
Figure 4—source data 3
Nppa mRNA in Sirt2f/f and cs-Sirt2-/- hearts as shown in Figure 4C.
- https://cdn.elifesciences.org/articles/85571/elife-85571-fig4-data3-v2.csv
-
Figure 4—source data 4
Nppb mRNA in Sirt2f/f and cs-Sirt2-/- hearts as shown in Figure 4D.
- https://cdn.elifesciences.org/articles/85571/elife-85571-fig4-data4-v2.csv
-
Figure 4—source data 5
Echo parameters in Sirt2f/f and cs-Sirt2-/- hearts as shown in Figure 4E.
- https://cdn.elifesciences.org/articles/85571/elife-85571-fig4-data5-v2.xlsx
Figure 4—figure supplement 1
SIRT1, SIRT3, and SIRT2 protein in the hearts of cs-Sirt2-/- mice.
-
Figure 4—figure supplement 1—source data 1
Uncropped gels for Figure 4—figure supplement 1.
- https://cdn.elifesciences.org/articles/85571/elife-85571-fig4-figsupp1-data1-v2.pptx
-
Figure 4—figure supplement 1—source data 2
Uncropped gels for Figure 4—figure supplement 1 unedited.
- https://cdn.elifesciences.org/articles/85571/elife-85571-fig4-figsupp1-data2-v2.pptx
Figure 4—figure supplement 2
cs-Sirt2-/- hearts from female mice are protected against trans-aortic constriction (TAC).
Ejection fraction (EF) and fractional shortening (FS) in female wild-type (WT) and cs-Sirt2-/- mice 7 and 14days after TAC (N=4).
-
Figure 4—figure supplement 2—source data 1
Ejection fraction (EF) and fractional shortening (FS) in female wild-type (WT) and cs-Sirt2-/- mice 7 and 14 days after TAC as shown in Figure 4—figure supplement 2.
- https://cdn.elifesciences.org/articles/85571/elife-85571-fig4-figsupp2-data1-v2.xlsx
Figure 5 with 3 supplements
SIRT2 interacts with nuclear factor (erythroid-derived 2)-like 2 (NRF2) and regulates its activity in the heart.
(A) Co-immunoprecipitation (IP) of SIRT2 and NRF2 in extracts of hearts from wild-type (WT) mice. (B) Endogenous NRF2 acetylation levels in the hearts of WT and Sirt2-/- mice at the baseline. …
-
Figure 5—source data 1
mRNA with overexpression of EV or SIRT2 as shown in Figure 5F.
- https://cdn.elifesciences.org/articles/85571/elife-85571-fig5-data1-v2.csv
-
Figure 5—source data 2
mRNA with overexpression of EV or SIRT2 as shown in Figure 5G.
- https://cdn.elifesciences.org/articles/85571/elife-85571-fig5-data2-v2.csv
-
Figure 5—source data 3
mRNA with overexpression of EV or SIRT2 as shown in Figure 5H.
- https://cdn.elifesciences.org/articles/85571/elife-85571-fig5-data3-v2.csv
-
Figure 5—source data 4
Uncropped gels for Figure 5.
- https://cdn.elifesciences.org/articles/85571/elife-85571-fig5-data4-v2.pptx
-
Figure 5—source data 5
Uncropped gels for Figure 5 unedited.
- https://cdn.elifesciences.org/articles/85571/elife-85571-fig5-data5-v2.pptx
-
Figure 5—source data 6
Uncropped gels for Figure 5 unedited.
- https://cdn.elifesciences.org/articles/85571/elife-85571-fig5-data6-v2.zip
Figure 5—figure supplement 1
Effects of SIRT2 overexpression on mRNA levels of non-nuclear factor (erythroid-derived 2)-like 2 (NRF2) targeted antioxidant genes.
N=5–6. Data presented as mean ± SEM.
-
Figure 5—figure supplement 1—source data 1
mRNA with overexpression of EV or SIRT2 as shown in Figure 5—figure supplement 1.
- https://cdn.elifesciences.org/articles/85571/elife-85571-fig5-figsupp1-data1-v2.csv
Figure 5—figure supplement 2
SIRT2 regulates nuclear factor (erythroid-derived 2)-like 2 (NRF2) and its target proteins.
(A) NRF2 protein levels in HL-1 cells treated with Sirt2 siRNA. (B–D) mRNA levels of NRF2 target genes in pentose phosphate pathway (B), quinone and glutathione-based detoxification (C), thioredoxin …
-
Figure 5—figure supplement 2—source data 1
Uncropped gels for Figure 5—figure supplement 2A.
- https://cdn.elifesciences.org/articles/85571/elife-85571-fig5-figsupp2-data1-v2.pptx
-
Figure 5—figure supplement 2—source data 2
Uncropped gels for Figure 5—figure supplement 2A unedited.
- https://cdn.elifesciences.org/articles/85571/elife-85571-fig5-figsupp2-data2-v2.pptx
-
Figure 5—figure supplement 2—source data 3
mRNA with overexpression of EV or SIRT2 as shown in Figure 5—figure supplement 2B–D.
- https://cdn.elifesciences.org/articles/85571/elife-85571-fig5-figsupp2-data3-v2.xlsx
Figure 5—figure supplement 3
Reactive oxygen species (ROS) levels as assessed by dihydroethidium (DHE) staining in neonatal rat cardiomyocytes (NRCMs) treated with control or Sirt2 siRNA after treatment with 500 µM H2O2.
N=5–6. Data presented as mean ± SEM.
-
Figure 5—figure supplement 3—source data 1
Fluorescence of cell death for Figure 5—figure supplement 3.
- https://cdn.elifesciences.org/articles/85571/elife-85571-fig5-figsupp3-data1-v2.csv
Figure 6
Nrf2 deletion and SIRT2 inhibitors protected against cardiac damage and cardiac hypertrophy.
Ejection fraction (EF) (A) and fractional shortening (FS) (B) in wild-type (WT), Sirt2-/-, and Sirt2-/-/Nrf2-/- double knockout (KO) mice 28 days after ischemia-reperfusion (I/R) (N=4–5). (C) …
-
Figure 6—source data 1
Ejection fraction (EF) in wild-type (WT), Sirt2-/-, and Sirt2-/-/Nrf2-/- mice after ischemia-reperfusion (I/R) as shown in Figure 6A.
- https://cdn.elifesciences.org/articles/85571/elife-85571-fig6-data1-v2.csv
-
Figure 6—source data 2
Fractional shortening (FS) in wild-type (WT), Sirt2-/-, and Sirt2-/-/Nrf2-/- mice after ischemia-reperfusion (I/R) as shown in Figure 6B.
- https://cdn.elifesciences.org/articles/85571/elife-85571-fig6-data2-v2.csv
-
Figure 6—source data 3
Ejection fraction (EF) with AGK2 as shown in Figure 6E.
- https://cdn.elifesciences.org/articles/85571/elife-85571-fig6-data3-v2.csv
-
Figure 6—source data 4
Fractional shortening (FS) with AGK2 as shown in Figure 6F.
- https://cdn.elifesciences.org/articles/85571/elife-85571-fig6-data4-v2.csv
-
Figure 6—source data 5
Left ventricular diameter during diastole (LVDd) with AGK2 as shown in Figure 6G.
- https://cdn.elifesciences.org/articles/85571/elife-85571-fig6-data5-v2.csv
-
Figure 6—source data 6
LVDs with AGK2 as shown in Figure 6H.
- https://cdn.elifesciences.org/articles/85571/elife-85571-fig6-data6-v2.csv
-
Figure 6—source data 7
IVSd with AGK2 as shown in Figure 6I.
- https://cdn.elifesciences.org/articles/85571/elife-85571-fig6-data7-v2.csv
-
Figure 6—source data 8
Posterior wall thickness during diastole (PWTd) with AGK2 as shown in Figure 6J.
- https://cdn.elifesciences.org/articles/85571/elife-85571-fig6-data8-v2.csv
Tables
Appendix 1—table 1
Primer sequences.
| Genes | Forward primer | Reverse primer | Species |
|---|---|---|---|
| Nppa | GGGTAGGATTGACAGGATTGG | CCTCCTTGGCTGTTATCTTC | Mouse |
| 18 s | AGTCCCTGCCCTTTGTACACA | CGATCCGAGGGCCTCACTA | |
| Actb | CTAAGGCCAACCGTGAAAAG | ACCAGAGGCATACAGGGACA | Mouse |
| Nppb | ATCCGTCAGTCGTTTGGG | CAGAGTCAGAAACTGGAGTC | Mouse |
| G6pd | GGCCAACCGTCTGTTCTACCT | CCACTATGATGCGGTTCCAGC | Rat |
| Pgd | CGGGTCATACTGCTCGTGAA | AGGTCCTGGCATCTTCTTGTCG | Rat |
| Nqo1 | CACTACGATCCGCCCCCAAC | GCGTGGGCCAATACAATCAGG | Rat |
| Gclc | GTCAAGGACCGGCACAAGGA | GAACATCGCCGCCATTCAGT | Rat |
| Gclm | TGCCACCAGATTTGACTGCATTT | TCCTGGAAACTTGCCTCAGAGAG | Rat |
| Gss | GAGGTCCGCAAAGAACCCCA | GAGCGTGAATGGGGCATACG | Rat |
| Gsr | TCACCCCGATGTATCACGCT | GCCCTGAAGCATCTCATCGC | Rat |
| Gpx4 | AGCAACAGCCACGAGTTCCT | ATCGATGTCCTTGGCTGCGA | Rat |
| Gsta1 | ACTTCGATGGCAGGGGGAGAA | TGGAACATCAAACTCCCATCATTCC | Rat |
| Gsta2 | TTGACGGGATGAAGCTGGCA | GTCAGATCTAAAATGCCTTCGGTGT | Rat |
| Gstm1 | CCAAGTGCCTGGACGCCTTC | ATAGGTGTTGAGAGGTAGCGGC | Rat |
| Gstp1 | CGTCCACGCAGCTTTGAGT | GTAACCACCTCCTCCTTCCAGC | Rat |
| Txn1 | AGTAGACGTGGATGACTGCCA | AGCACCAGAGAACTCCCCAAC | Rat |
| Prdx1 | TCAGATCCCAAGCGCACCAT | AGCGGCCAACAGGAAGATCA | Rat |
| Txnrd1 | AATGCTGGAGAGGTGACGCA | GATGTCTCCCCCAGAACGCT | Rat |
| Sirt1 | CAGTGTCATGGTTCCTTTGC | CACCGAGGAACTACCTGAT | Mouse |
| Sirt3 | GCTGCTTCTGCGGCTCTATAC | GAAGGACCTTCGACAGACCGT | Mouse |
| Sirt4 | GTGGAAGAATAAGAATGAGCGGA | GGCACAAATAACCCCGAGG | Mouse |
| Sirt5 | CCACCGACAGATTCAGGTTT | TTCCCGTTAGTGCCCTGCTTTA | Mouse |
| Sirt6 | ATGTCGGTGAATTATGCAGCA | GCTGGAGGACTGCCACATTA | Mouse |
| Sirt7 | CAGGTGTCACGCATCCTGAG | GCCCGTGTAGACAACCAAGT | Mouse |
| Cat | CCAGCCAGCGACCAGATGAA | CCTATTGGGTTCCCGCCTCC | Rat |
| Sod1 | AACTGAAGGCGAGCATGGGTT | ATGCCTCTCTTCATCCGCTGG | Rat |
| Sod2 | GGGGCCATATCAATCACAGCA | GAACCTTGGACTCCCACAGAC | Rat |
| Sod3 | ACGTTCTTGGGAGAGCTTGT | CTGCTAAGTCGACACCGGAC | Rat |
| Actb | GGCTCCTAGCACCATGAAGA | CAGTGAGGCCAGGATAGAGC | Rat |
| Hprt 1 | CCCTCAGTCCCAGCGTCGTG | CGAGCAAGTCTTTCAGTCCTGTCC | Rat |
| B2m | CCGTGATCTTTCTGGTGCTTG | GAGACACGTAGCAGTTGAGGA | Rat |
| G6pd | GTCTTTGCTCGGTGCTTGTC | AGCATAGAGGGCCTTACGGA | Mouse |
| Nqo1 | TCTCTGGCCGATTCAGAGTG | CCAGACGGTTTCCAGACGTT | Mouse |
| Gclm | ATGACCCGAAAGAACTGCTC | TGGGTGTGAGCTGGAGTTAAG | Mouse |
| Gclc | ACTGAATGGAGGCGATGTTCTT | CAGAGGGTCGGATGGTTGG | Mouse |
| Gss | GCACCGACACGTTCTCAATG | TAGCACCACCGCATTAGCTG | Mouse |
| Gsr | ATGTTGACTGCCTGCTCTGG | ATCCGTCTGAATGCCCACTT | Mouse |
| Gpx4 | GTACTGCAACAGCTCCGAGT | ATGCACACGAAACCCCTGTA | Mouse |
| Gsta2 | CCAGGACTCTCACTAGACCGT | CCCGGGCATTGAAGTAGTGA | Mouse |
| gstm1 | ATACACCATGGGTGACGCTC | TCCATCCAGGTGGTGCTTTC | Mouse |
| Gstp1 | GTCTACGCAGCACTGAATCC | GGGAGCTGCCCATACAGACA | Mouse |
| Txn1 | GCGCTCCGCCCTATTTCTAT | CCTCCTGAAAAGCTTCCTTGC | Mouse |
| Prdx1 | ACTGACAAACATGGTGAAGTGTG | TACAAGAGTTTCTTCTGGCTGC | Mouse |
| Txnrd1 | GAATGGACAGTCCCATCCCG | AAGCCCACGACACGTTCATC | Mouse |
| Actb | TAAAACCCGGCGGCGCA | GTCATCCATGGCGAACTGGT | Mouse |
| Hprt1 | AGAGCGTTGGGCTTACCTCA | TGGTTCATCATCGCTAATCACG | Mouse |
| B2m | ACGCCTGCAGAGTTAAGCAT | TGATCACATGTCTCGATCCCAG | Mouse |
Appendix 1—key resources table
| Reagent type (species) or resource | Designation | Source or reference | Identifiers | Additional information |
|---|---|---|---|---|
| Strain, strain background (Mus musculus, male, C57BL/6) | Sirt2 knockout mice | Dr. Gius Lab | refer to: SIRT2 Maintains Genome Integrity and Suppresses Tumorigenesis through Regulating APC/C Activity. | |
| Strain, strain background (Mus musculus, male, C57BL/6) | Sirt2 flox/flox mince | Dr. Gius Lab | refer to: SIRT2 deletion enhances KRAS-induced tumorigenesis in vivo by regulating K147 acetylation status | |
| Strain, strain background (Mus musculus, male, C57BL/6) | Nrf2 knockout mice | the Jackson Laboratory | RRID:IMSR_JAX:017009 | |
| Strain, strain background (Rattus norvegicus domestica, female) | Sprague–Dawley rat | Charles River | ||
| Antibody | Rabbit polyclonal SIRT1 antibody | Sigma | 07–131 | WB (1:1000) |
| Antibody | Rabbit polyclonal SIRT2 antibody | Sigma | S8447 | WB (1:1000) |
| Antibody | Rabbit mAb SIRT3 antibody | Cell Signaling Technology | Rabbit mAb #5490 | WB (1:1000) |
| Antibody | Rabbit polyclonal anti-HPRT antibody | Proteintech | 150-59-1-AP | WB (1:5000) |
| Antibody | Mouse monoclonal anti-GAPDH antibody | Proteintech | 60004–1-Ig | WB (1:10000) |
| Antibody | Rabbit mAb NRF2 antibody | Cell Signaling Technology | Rabbit mAb #20733 | WB (1:1000) |
| Antibody | Rabbit polycloncal NRF2 antibody | Abcam | ab31163 | WB (1:1000) |
| Antibody | HRP-conjugated donkey polyclonal anti-mouse IgG antibody | Jackson ImmunoResearch | 715-035-150 | WB (1:5000) |
| Antibody | HRP-conjugated donkey polyclonal anti-rabbit IgG antibody | Jackson ImmunoResearch | 711-035-152 | WB (1:5000) |
| Antibody | Rabbit Anti beta Actin antibody | Abcam | ab8227 | WB (1:2000) |
| Antibody | RabbTBP antibody | Abcam | ab63766 | WB (1:2000) |
| Antibody | Rabbit mAb SIRT6 antibody | Cell Signaling Technology | Rabbit mAb #12486 | WB (1:1000) |
| Antibody | Mouse Flag-M2 monoclonal antibody | Sigma | F1804 | WB: (1:2000); IP(1:xxx) |
| Antibody | Acetyl Lysine Antibody, Agarose | immunechem | ICP0388-2MG | IP: 1:10 |
| Chemical compound, drug | Propodium Iodine | Sigma | P4170-10MG | |
| Chemical compound, drug | Hoechst 34432 | Life Technology | 62249 | |
| Chemical compound, drug | Cycloheximide | Sigma | 1810 | |
| Chemical compound, drug | Paraformaldehyde | Thermo Fisher Scientific | AC416780250 | |
| Chemical compound, drug | RIPA Buffer | Thermo Fisher Scientific | 89901 | |
| Chemical compound, drug | ProteaseArrest Protease Inhibitor | G-Biosciences | 786–437 | |
| Chemical compound, drug | 10% formalin | Fisher Scientific | FLSF1004 | |
| Chemical compound, drug | BrdU | Sigma | 19–160 | |
| Chemical compound, drug | vitamin B12 | Sigma | V2876 | |
| Chemical compound, drug | FBS | Bio-Techne | S11550 | |
| Chemical compound, drug | penicillin–streptomycin | Cytiva | SV30010 | |
| Chemical compound, drug | Lipofectamine 2000 Transfection Reagent | Invitrogen, Thermo Fisher Scientific | 11668027 | |
| Chemical compound, drug | Dharmafect transfection reagent | Horizon | 2001–03 | |
| Chemical compound, drug | AGK2 | Selleckchem | S7577 | |
| Chemical compound, drug | hydrogen peroxide | Fisher Scientific | H324-500 | |
| Chemical compound, drug | Normal Rabbit IgG | Sigma | 12–370 | |
| Chemical compound, drug | DMSO | Sigma | D4540 | |
| Cell line | H9c2 | ATCC | CRL-1446 | |
| Other | DMEM | Corning | 10-013CV | |
| Commercial assay or kit | RNA-STAT60 | Teltest | Cs-502 | |
| Commercial assay or kit | DNAse I | Ambion | AM2222 | |
| Commercial assay or kit | PerfeCTa SYBR Green FastMix | Quanta | 95074–05 K | |
| Commercial assay or kit | qScript cDNA Synthesis Kit | Quanta | 95047–500 | |
| Commercial assay or kit | SuperSignal West Pico PLUS Chemiluminescent Substrate | Pierce | 34579 | |
| Commercial assay or kit | BCA Protein Assay Kit | Pierce | 23225 | |
| Commercial assay or kit | NE-PER Nuclear and Cytoplasmic Extraction Reagents | Pierce | PI78835 | |
| Commercial assay or kit | Trichrome Stain (Masson) Kit | Sigma | HT15-1KT | |
| Commercial assay or kit | Protein A Agarose | Roche | 11719408001 | |
| Commercial assay or kit | dihydroethidium (DHE) assay | Thermo Fisher Scientific | D11347 | |
| Sequence-based reagent | Rat Sirt2 siRNA | Horizon Discovery | M-082072-01-0005 | siGENOME Rat Sirt2 (361532) siRNA |
| Recombinant DNA reagent | Wildtype SIRT2 plasmid | Dr. Gius Lab | refer to: SIRT2 Maintains Genome Integrity and Suppresses Tumorigenesis through Regulating APC/C Activity | |
| Software, algorithm | GraphPad Prism | GraphPad | Version 9 | |
| Software, algorithm | ImageJ | NIH | 1.53 c |
